MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Insulet Company Profile (NASDAQ:PODD)

Consensus Ratings for Insulet (NASDAQ:PODD) (?)
Ratings Breakdown: 6 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $36.92 (29.35% upside)

Analysts' Ratings History for Insulet (NASDAQ:PODD)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016WedbushReiterated RatingOutperform$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Piper JaffrayReiterated RatingOverweight$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Sterne Agee CRTReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Canaccord GenuityReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2016William BlairUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Feltl & Co.UpgradeHold -> Buy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Benchmark Co.UpgradeHold -> Buy$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Robert W. BairdLower Price TargetNeutral$35.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Northland SecuritiesReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015Leerink SwannReiterated RatingBuy$40.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015Jefferies GroupBoost Price TargetBuy$30.00 -> $39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2015JPMorgan Chase & Co.Boost Price TargetNeutral$26.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2015OppenheimerLower Price TargetMarket Perform$33.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2015Raymond JamesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014JMP SecuritiesReiterated RatingMarket Outperform$9.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014Northcoast ResearchInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2014Off Wall StreetReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Insulet (NASDAQ:PODD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Insulet (NASDAQ:PODD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.29)($0.29)($0.29)
Q2 20163($0.21)($0.14)($0.18)
Q3 20162($0.17)($0.15)($0.16)
Q4 20163($0.14)($0.08)($0.11)
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)
Dividend History for Insulet (NASDAQ:PODD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Insulet (NASDAQ:PODD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Insulet (NASDAQ:PODD)
DateHeadline
06/17/16 04:08 PMINSULET CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits -
06/16/16 06:08 PMStudies Find Omnipod System Effective in Controlling Blood Glucose Levels Among Patients With Diabetes
06/16/16 06:08 PMInsulet touts new data showing reduced A1c levels with Omnipod system | American Diabetes Assn. 2016 Scientific Sessions
06/13/16 05:25 PMMedtronic presents pivotal artificial pancreas data at ADA, as Insulet details its own plans
06/11/16 12:09 PMNew Data Demonstrate Benefits of Insulet's Omnipod® System for People with Type 1 and Type 2 Diabetes - [at noodls] - Two Publications in the Journal of Diabetes Science and Technology BILLERICA, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its Omnipod ...
06/11/16 12:00 PMNew Data Demonstrate Benefits of Insulet’s Omnipod® System for People with Type 1 and Type 2 Diabetes - [Business Wire] - Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod Insulin Management System , today announced two online publications of new data in the Journal of Diabetes Science and Technology that provide evidence supporting the benefits of the Omnipod System in patients with type 1 and type 2 diabetes.
06/10/16 08:54 AMInsulet updates on artificial pancreas, pipeline products
06/10/16 05:09 AMInsulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet's Clinical Team - [at noodls] - Insulet's Clinical Team Receives Certification in Advanced Diabetes Educator in Pump Therapy (ADEPT™) Program BILLERICA, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), ...
06/10/16 05:00 AMInsulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet’s Clinical Team - [Business Wire] - Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that almost 100 members of Insulet’s North American clinical team have completed a customized certification program designed and led by the Joslin Diabetes Center for Insulet.
06/08/16 05:48 PMInsulet to Present Omnipod® Clinical Studies on Type 1 and Type 2 Diabetes During the American Diabetes Association's 76th Scientific Sessions - [at noodls] - Company Presentations Include Compelling Clinical Data Demonstrating the Efficacy of the Omnipod System on Glycemic Control in Patients with Type 1 and Type 2 Diabetes Dr. Frank Doyle to Share Exciting ...
06/08/16 05:38 PMInsulet to Present Omnipod® Clinical Studies on Type 1 and Type 2 Diabetes During the American Diabetes Association’s 76th Scientific Sessions - [Business Wire] - Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced new clinical data for the Company’s Omnipod System will be presented at the American Diabetes Association 76th Scientific Sessions in New Orleans, La., June 10-14, 2016.
06/08/16 12:44 PMInsulet Corp. – Value Analysis (NASDAQ:PODD) : June 8, 2016 -
06/07/16 07:18 AMInsulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : June 7, 2016 -
05/27/16 01:34 PMBiotech Stocks To Focus: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Insulet Corporation (NASDAQ:PODD) - Is stories - Biotech Stocks To Focus: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Insulet Corporation (NASDAQ:PODD)Is storiesIn most recently trading session on 5/26/2016, Insulet Corporation (NASDAQ:PODD) dropped -1.93% while traded on 1.57 million shares versus it's an average volume of 562.55 thousand shares. The company recorded the last trade with the price of $29.50.and more »
05/26/16 12:38 PMInsiders Are Gradually Buying Insulet Corporation (NASDAQ:PODD) - Wall Street Hints and News - Insiders Are Gradually Buying Insulet Corporation (NASDAQ:PODD)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Insulet Corporation (NASDAQ:PODD) have increased their position in the stock by 5.86% over the past 6 months. ... Insiders buy and sell their own company's stock all the time, though their trading is ...and more »
05/26/16 12:38 PMPermian Investment Partners LP Decreased Stake in Insulet Corp (NASDAQ:PODD) by $12.05 Million as Shares ... - CCH Daily News - Permian Investment Partners LP Decreased Stake in Insulet Corp (NASDAQ:PODD) by $12.05 Million as Shares ...CCH Daily NewsPermian Investment Partners Lp decreased its stake in Insulet Corp (NASDAQ:PODD) by 48.44% based on its latest 2016Q1 regulatory filing with the SEC. Permian Investment Partners Lp sold 365,180 shares as the company's stock declined 10.52% while ...Insulet Corporation (NASDAQ:PODD) Shorts Decreased by 2.24% After Short CoveringFranklin IndependentEarnings Estimates Report: Insulet Corporation (NASDAQ:PODD)CWRU ObserverInsulet Corporation (NASDAQ:PODD) Quarterly EPS From Continuing Operations Stands At $-0.19Equities FocusThe Post -Risers & Fallersall 7 news articles »
05/23/16 05:06 AMInsulet Launches New Omnipod® Podder™ Community Platform - [at noodls] - New Platform Provides Enhanced Support, Information, and Social Engagement for Growing Community of Podders BILLERICA, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), ...
05/18/16 11:48 AMTop Buys by Top Brass: EVP Human Resources Thomas's $129.1K Bet on PODD - A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So in this series we look at the largest insider buys by the ''top brass'' over the trailing six month period, one of which was a total of $129.1K invested across 2 purchases by Bradley A. Thomas, EVP Human Resources at Insulet Corp (NASD: PODD).
05/13/16 03:02 PMINSULET CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/04/16 07:38 AMInsulet Corp. breached its 50 day moving average in a Bearish Manner : PODD-US : May 4, 2016 -
05/04/16 05:07 AMINSULET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/03/16 02:37 PMInsulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidance - The leader in tubeless insulin pump technology beat its revenue guidance on strength across all segments. Thanks largely to the success of Amgen’s Neulasta Onpro kit, drug delivery revenue jumped 224%.
05/03/16 02:22 PMBRIEF-Insulet reaffirms second quarter and full year 2016 guidance - * Insulet reaffirms second quarter and full year 2016 guidance
05/03/16 01:50 PMInsulet Reaffirms Second Quarter and Full Year 2016 Guidance - [at noodls] - BILLERICA, Mass., May 3, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod Insulin Management System (OmniPod ...
05/02/16 12:30 PMInsulet Corp. :PODD-US: Earnings Analysis: Q1, 2016 By the Numbers -
04/29/16 01:21 PMINSULET CORP Files SEC form 10-Q, Quarterly Report -
03/28/16 02:45 PMShort Interest In Insulet Increases 15.2% - The most recent short interest data has been released by the NASDAQ for the 03/15/2016 settlement date, which shows a 705,381 share increase in total short interest for Insulet Corp (PODD), to 5,359,798, an increase of 15.16% since 02/29/2016. Total short ...
03/02/16 03:05 PMInsulet Announces Organizational Enhancements - [PR Newswire] - BILLERICA, Mass., March 2, 2016 /PRNewswire/ -- Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced the promotion of Shacey Petrovic to the newly-created role of President, Insulet Diabetes Products and the recent appointment of Charles Alpuche as Senior Vice President of Global Manufacturing and Operations. As President, Insulet Diabetes Products, Ms. Petrovic will lead the Company's global growth initiatives within the diabetes business, including cross-functional integration, financial investments and achievement of all operating targets and will continue to oversee sales, marketing, managed care, customer care and strategic partnerships.
02/29/16 10:25 AMInsulet Corp. Earnings Analysis: 2015 By the Numbers -
02/29/16 07:14 AMINSULET CORP Files SEC form 10-K, Annual Report -
02/28/16 01:54 PMHealthcare ratings roundup - upgrades/downgrades - Achillion Pharmaceuticals (ACHN +7.4%) upgraded to Outperform from Neutral with a $10 (36% upside) price target by Baird Insulet (PODD +8.5%) upgraded to Buy ... Equal Weight from Overweight by Stephens & Co. Radius Health (RDUS-2.8%) downgraded to Hold ...
02/26/16 03:41 PMWhy Insulet Corporation is Soaring Today - A fourth quarter earnings report pack with good news puts Insulet's investors in a good mood.
02/26/16 03:41 PMInsulet Pumps Out 38% Revenue Growth in Q4, Expects 30% Growth in 2016 - The leader in tubeless insulin pump technology signed an agreement with a partner to develop and incorporate the advanced artificial pancreas algorithm into its OmniPod System.
02/26/16 07:40 AMInsulet upgraded by The Benchmark Company -
02/25/16 11:08 PMEdited Transcript of PODD earnings conference call or presentation 25-Feb-16 9:30pm GMT -
02/25/16 03:30 PMInsulet Corp Earnings Call scheduled for 4:30 pm ET today -
02/25/16 03:24 PMInsulet reports 4Q loss -
02/25/16 03:06 PMINSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition -
02/25/16 03:01 PMInsulet Reports Fourth Quarter and Full Year 2015 Financial Results - [PR Newswire] - BILLERICA, Mass., Feb. 25, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod ® Insulin Management System (OmniPod System), today announced ...
02/25/16 08:42 AMSell Insulet, Empire Warns -
02/25/16 06:07 AMQ4 2015 Insulet Corp Earnings Release - After Market Close -
02/25/16 06:00 AMInsulet Announces Development Partner for the OmniPod Artificial Pancreas - [PR Newswire] - BILLERICA, Mass., Feb. 25, 2016 /PRNewswire/ -- Insulet Corporation (PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced a license agreement and partnership with Mode AGC (Automated Glucose Control LLC), to develop and incorporate the advanced artificial pancreas algorithm created by renowned researchers Francis Doyle PhD, Eyal Dassau PhD, and Howard Zisser MD. This alliance marks a significant step forward in Insulet's mission to improve the quality of life for individuals with insulin-dependent diabetes.
02/17/16 01:22 PMInsulet Corporation (NASDAQ:PODD) Shorts Decreased by 3.56% After Short Covering - fdanewsalert.com - Insulet Corporation (NASDAQ:PODD) Shorts Decreased by 3.56% After Short Coveringfdanewsalert.comThe stock of Insulet Corporation (NASDAQ:PODD) registered a decrease of 3.56% in short interest. PODD's total short interest was ... Moreover, Bridger Management Llc has 3.83% invested in the company for 2.17 million shares. The California-based Dafna ...
02/16/16 01:15 PMAnalyst Coverage Updates - Insulet Corporation (NASDAQ:PODD) - Risers & Fallers - Analyst Coverage Updates - Insulet Corporation (NASDAQ:PODD)Risers & FallersInsulet Corporation has a 50 day moving average of 33.12 and a 200 day moving average of 32.21. The stock's market capitalization is 1.42B, it has a 52-week low of 23.94 and a 52-week high of 40.21. The share price of the company (NASDAQ:PODD) was ...and more »
02/12/16 01:04 PMInsulet Corporation (PODD) Hits New 52-week Low During February 11 Session - Equities.com - Insulet Corporation (PODD) Hits New 52-week Low During February 11 SessionEquities.comInsulet Corporation (PODD) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $25.35, Insulet Corporation dropped to $24.21 for a new 52-week low. By the closing bell, the company's stock was at ...and more »
02/10/16 12:20 PMINSULET CORP Files SEC form 8-K, Change in Directors or Principal Officers -
02/09/16 03:05 PMInsulet Appoints David A. Lemoine to Board of Directors - [PR Newswire] - BILLERICA, Mass., Feb. 9, 2016 /PRNewswire/ -- Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that David A. Lemoine has been appointed to Insulet's Board of Directors. Mr. Lemoine brings over 40 years of audit and finance experience and a deep knowledge of accounting, financial reporting and internal controls to the Insulet Board of Directors.
02/02/16 03:18 PMINSULET CORP Files SEC form 8-K, Regulation FD Disclosure -
02/02/16 03:16 PM4:16 pm Insulet to sell its Neighborhood Diabetes supplies business to Liberty Medical for $5 mln cash - expected to close in Q1 -
02/02/16 03:15 PMInsulet to Divest Neighborhood Diabetes Supplies Business - [PR Newswire] - BILLERICA, Mass., Feb. 2, 2016 /PRNewswire/ -- Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced it has entered into a definitive agreement to sell its wholly-owned Neighborhood Diabetes supplies business to Liberty Medical, LLC (Liberty Medical), a leading provider of mail order medical supplies, for $5 million in cash. The transaction, which is expected to close in the first quarter of 2016, is subject to certain customary closing conditions.
About Insulet

Insulet logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). The Company purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The Company purchases OmniPods pursuant to its agreement with Flextronics. The OmniPod System is available in Europe, Canada and Israel.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: PODD
  • CUSIP: 45784P10
Key Metrics:
  • Previous Close: $28.54
  • 50 Day Moving Average: $29.71
  • 200 Day Moving Average: $32.10
  • P/E Ratio: N/A
  • P/E Growth: -1.80
  • Market Cap: $1.63B
  • Current Quarter EPS Consensus Estimate: $-0.66 EPS
Additional Links:
Insulet (NASDAQ:PODD) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha